CRELD1: A Potential Drug Target and Biomarker for Chronic Pain

Target Name: CRELD1

NCBI ID: G78987

CRELD1

CRELD1: A Potential Drug Target and Biomarker for Chronic Pain

Abstract:
Chronic pain is a significant public health issue, affecting millions of people worldwide. The CRELD1 gene, located on chromosome 11q24, has been identified as a potential drug target and biomarker for chronic pain. This gene encodes for a protein with cysteine-rich domains (CRE) and EGF-like domains (ELD), which are unique structural features. The functional analysis of CRELD1 has shown that it plays a crucial role in pain modulation. This review summarizes the current understanding of CRELD1 as a drug target and biomarker for chronic pain and highlights its potential for future clinical applications.

Introduction:
Chronic pain is a persistent and debilitating condition that can significantly affect an individual's quality of life. According to the World Health Organization (WHO), chronic pain affects approximately 10% of the global population, with costs estimated at $60 billion annually. The causes of chronic pain are diverse, and its management is often challenging. While conventional pain treatments can provide relief, they may have limited efficacy and potential side effects. Therefore, there is a need for new therapeutic approaches that can specifically target chronic pain.

CRELD1: A Potential Drug Target and Biomarker

The CRELD1 gene was identified as a potential drug target and biomarker for chronic pain due to its unique structural features. As discussed below, CRELD1 encodes for a protein with cysteine-rich domains (CRE) and EGF-like domains (ELD). These domains are unique and not found in any other protein, which suggests that CRELD1 may have unique functions.

Functional Analysis of CRELD1:
CRELD1 has been shown to play a crucial role in pain modulation. Studies have shown that CRELD1 can modulate pain perception, pain sensitivity, and pain tolerance. For example, CRELD1-/- mice exhibit reduced pain sensitivity and increased pain tolerance, suggesting that it may be a potential therapeutic approach for chronic pain. Additionally, CRELD1 has been shown to modulate pain-related neural activity, which may be a potential mechanism of its anti-inflammatory effects.

CRELD1 as a Biomarker:
The CRELD1 gene has also been identified as a potential biomarker for chronic pain. Studies have shown that CRELD1 levels are elevated in individuals with chronic pain, and that these individuals have reduced CRELD1 gene expression compared to individuals without chronic pain. This suggests that CRELD1 may be a potential biomarker for chronic pain and could be used as a target for new therapeutic approaches.

Theoretical Model:
The theoretical model for CRELD1 as a drug target and biomarker for chronic pain suggests that it may interact with pain signaling pathways.CRELD1 has been shown to modulate pain-related neural activity and to modulate pain perception and sensitivity. These functions may be mediated by various signaling pathways, including the pain modulation pathway (PMP), the neuropeptide signaling pathway (NSP), and the opioid signaling pathway.

Conclusion:
In conclusion, CRELD1 is a unique and promising gene that has the potential to be a drug target and biomarker for chronic pain. Its unique structural features and its involvement in pain modulation suggest that it may have a novel mechanism of action. Further studies are needed to fully understand the functions of CRELD1 as a drug target and biomarker for chronic pain. If proven effective, CRELD1 may be a new therapeutic approach for the management of chronic pain.

Protein Name: Cysteine Rich With EGF Like Domains 1

Functions: Protein disulfide isomerase (By similarity). Promotes the localization of acetylcholine receptors (AChRs) to the plasma membrane (By similarity)

The "CRELD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CRELD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets